Huntington's Disease: Opportunity Assessment and Forecast

PUBLISHED: October 8, 2025

PAGES: 84 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

This report covers the 7MM and provides an Excel-based forecast model for the Huntington's Disease market through 2034.

The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key area of development. Companies are pursuing various mechanisms to achieve this, including gene therapies, antisense oligonucleotides (ASOs), and oral therapeutics. The HD market across the 7MM was valued at $0.3 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 27.4%, reaching $3.8 billion by 2034. A key driver of growth will be the launch of seven late-stage pipeline products, including the first DMTs for HD.

Scope

Overview of Huntington's Disease (HD), including epidemiology, symptoms, diagnosis, and disease management.
Annualized HD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HD market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HD. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the 7MM HD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM HD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHCOA055

Contents
Abbreviations
Related Reports
Executive Summary
Disease Overview
Overview of HD
Pathophysiology of HD
Staging Systems of HD
Huntington's Disease Integrated Staging System
HD SWOT Analysis
Epidemiology
Diagnosed Incident Cases of Manifest HD, Both Sexes, All Ages, 2024-34
Age-Specific Trends in Diagnosed Incident Cases of Manifest HD, Both Sexes, 2024
Sex-Specific Diagnosed Incident Cases of Manifest HD, All Ages, 2024
Diagnosed Prevalent Cases of All HD (Premanifest and Manifest Combined), Both Sexes, All Ages, 2024-34
Diagnosed Prevalent Cases of Premanifest HD, Both Sexes, All Ages, 2024-34
Diagnosed Prevalent Cases of Manifest HD, Both Sexes, All Ages, 2024-34
Age-Specific Trends in Diagnosed Prevalent Cases of Manifest HD, Both Sexes, 2024
Sex-Specific Diagnosed Prevalent Cases of Manifest HD, All Ages, 2024
Diagnosed Prevalent Cases of Manifest HD by Type, All Ages, Both Sexes, 2024
Diagnosed Prevalent Cases of Adult-Onset Manifest HD by Stage, All Ages, Both Sexes, 2024
Sources and Methodology for Diagnosed Incident Cases of Manifest HD
Sources and Methodology for Diagnosed Prevalent Cases of All HD
Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
Sources and Methodology for Manifest HD by Type
Sources and Methodology for Adult-Onset Manifest HD by Stage
Sources and Methodology for Diagnosed Incident Cases of Manifest HD
Sources and Methodology for Diagnosed Prevalent Cases of All HD
Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
Current Treatment Options
Treatment Paradigm
Current Treatment Options
Product Profile: Bausch Health's Xenazine/Nitoman/Choreazine (tetrabenazine)
Product Profile: Teva's Austedo/Austedo XR (deutetrabenzine/deutetrabenzine ER)
Product Profile: Neurocrine Biosciences' Ingrezza/Ingrezza Sprinkle (valbenazine)
Product Profile: Sanofi's Tiaprizal/Tiapridal/Sereprile/Gramalil (tiapride)
Patient Flow: HD in 2024 Across 7MM
Unmet Needs and Opportunities
Unmet Needs in HD
Disease-Modifying Therapies
Early Diagnosis and Consensus on Disease Staging
Treatment Options for Cognitive and Psychiatric Symptoms
R&D Strategies
Trends in Clinical Trial Design in HD
Trends in Deal-Making in HD
Pipeline Assessment
HD Pipeline Overview
Late-Stage Pipeline Agents for HD
Product Profile: SOM Biotech's SOM-3355 (bevantolol hydrochloride)
Product Profile: Prilenia Therapeutics' Huntexil (pridopidine)
Product Profile: Roche's RG6042 (tominersen)
Product Profile: Wave Life Sciences' WVE-003
Product Profile: uniQure's AMT-130 (ifezuntirgene inilparvovec)
Product Profile: PTC Therapeutics/Novartis's PTC518 (votoplam)
Product Profile: Skyhawk Therapeutics' SKY-0515
HD: Clinical Trials (Phase II/III) Overview
Market Outlook
HD Market Forecast
Market Drivers and Barriers